نتایج جستجو برای: ccnu
تعداد نتایج: 395 فیلتر نتایج به سال:
Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB-mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our objective was to determine the antitumor effect of GSK-3 inhibitor 9-ING-41 in combination with chemoth...
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in this setting. The study was designed as multicenter, randomized phase II trial, prece...
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM). In this study, we performed gene expression profiling (DASL and RNA-seq) of formalin-fixed, paraffin-embedded tumor material from participan...
This case report describes a 10-year-old castrated male Russian Blue cat who was referred to the hospital for respiratory distress and coughing. Tests FeLV FIV infection were negative. Pleural fluid removed subjected cytological lymphocyte clonality analysis. Thoracic radiography ultrasonography confirmed atelectasis in some pulmonary lobes. The diagnosed with stage III small- medium-cell T cel...
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced, progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control In medicine, it is not infrequent that treatments in different institutions evolve over a period of time, by accepted use, with modest background data. In the realm of palliative chemotherapy, it is clear t...
Abstract AIMS Lomustine (CCNU) based regimens are frequently used for recurrent glioblastoma multiforme (GBM). The usual CCNU regimen is 100-130mg/m2, day 1 x 6-weekly cycle up to 6 cycles. Efficacy limited, with median progression-free survival (PFS) approximating 1.0-3.0 months higher haematological toxicities, particularly thrombocytopenia around 13-25%. Clatterbridge Cancer Centre, UK, has ...
BACKGROUND To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU. To reduce neurotoxicity, whole-brain irradiation was reserved for patients not responding to chemotherapy. PATIENTS AND METHODS High-dose MTX was applied on days 1, 15, and 30, procarbazine...
Activity of GFR/PI3K/AKT pathway inhibitors in glioblastoma clinical trials has not been robust. We hypothesized variations in the pathway between tumors contribute to poor response. We clustered GBM based on AKT pathway genes and discovered new subtypes then characterized their clinical and molecular features. There are at least 5 GBM AKT subtypes having distinct DNA copy number alterations, e...
Background In the EORTC 1410/INTELLANCE 2 randomised, phase II study (NCT02343406), with antibody–drug conjugate depatuxizumab mafodotin (Depatux-M, ABT-414) in patients recurrent EGFR-amplified glioblastoma, primary end-point (overall survival) was not met, and drug had ocular dose-limiting toxicity. This reports results from prespecified health-related quality of life (HRQoL) neurological det...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید